Updated: January 17, 2026
Alternatives to Baqsimi If You Can't Fill Your Prescription
Author
Peter Daggett

Summarize with AI
- Why Would You Need an Alternative to Baqsimi?
- Alternative 1: Gvoke (Glucagon Injection Autoinjector)
- Alternative 2: Zegalogue (Dasiglucagon Injection)
- Alternative 3: Traditional Glucagon Emergency Kits (GlucaGen)
- How Do These Alternatives Compare to Baqsimi?
- Which Alternative Should You Ask About?
- Keep Trying to Get Baqsimi
Can't fill your Baqsimi prescription? Here are the best FDA-approved glucagon alternatives to keep you safe until Baqsimi is available again.
Baqsimi (glucagon nasal powder 3 mg) is the only needle-free, ready-to-use glucagon rescue treatment on the US market. It's a breakthrough product that has made severe hypoglycemia emergencies far less daunting for patients and caregivers. But what happens when Baqsimi isn't available at your local pharmacy or is out of reach financially?
The good news is that there are several FDA-approved alternatives to Baqsimi. Each works differently, but they all share the same goal: reversing severe hypoglycemia quickly and safely. Here's what you need to know about each option.
Why Would You Need an Alternative to Baqsimi?
There are a few common reasons patients look for Baqsimi alternatives:
Baqsimi is temporarily out of stock at nearby pharmacies.
Insurance doesn't cover Baqsimi or prior authorization is pending.
The cash price (~$300-$400 per device) is cost-prohibitive.
A nasal condition makes intranasal administration a concern.
Important: Always consult your doctor or pharmacist before switching to a different glucagon product. They can help you choose the right alternative and ensure your caregiver knows how to use it.
Alternative 1: Gvoke (Glucagon Injection Autoinjector)
Gvoke (glucagon injection) by Xeris Pharmaceuticals is one of the closest alternatives to Baqsimi. Like Baqsimi, it's a ready-to-use glucagon product — no mixing required. It comes in two forms:
Gvoke HypoPen: An autoinjector that works similarly to an EpiPen — remove the cap and press against the skin.
Gvoke PFS: A prefilled syringe option for those who prefer syringe delivery.
Gvoke is approved for patients ages 2 and older. Clinical trials show it achieves treatment success in over 98% of cases, comparable to Baqsimi. The main trade-off is that it requires a subcutaneous injection, which may be a concern for needle-averse caregivers. Dosing is weight-based for pediatric patients under 12.
Alternative 2: Zegalogue (Dasiglucagon Injection)
Zegalogue (dasiglucagon) by Zealand Pharma is a newer glucagon-like analog injection available in an autoinjector or prefilled syringe. Dasiglucagon isn't identical to glucagon — it's an analog with seven amino acid substitutions designed for stability and fast action.
Zegalogue is approved for ages 6 and older. It can be stored in the refrigerator for up to 3 years or at room temperature for up to 1 year. Clinical data shows it achieves treatment success in over 98% of patients, similar to Baqsimi and Gvoke.
Alternative 3: Traditional Glucagon Emergency Kits (GlucaGen)
Traditional glucagon kits like GlucaGen (Novo Nordisk) have been available for decades and remain widely stocked at most pharmacies. They are typically the least expensive glucagon option. However, they require reconstitution: mixing the glucagon powder with a liquid before injection. In a stressful emergency, this step can be difficult for caregivers unfamiliar with the process.
If your only option is a traditional glucagon kit, make sure your caregivers are well-trained on the reconstitution process before an emergency happens. Practice runs are strongly encouraged.
How Do These Alternatives Compare to Baqsimi?
A 2023 study published in Diabetes Therapy performed an indirect treatment comparison of all three ready-to-use glucagon options (Baqsimi, Gvoke, and Zegalogue). Key findings:
All three achieved treatment success in over 98% of patients.
Baqsimi achieved a statistically lower mean maximum blood glucose (168 mg/dL vs. Gvoke 220 mg/dL and Zegalogue 190 mg/dL), which may mean less post-treatment hyperglycemia.
No significant differences in serious adverse events across all three.
In plain terms: if you need glucagon in an emergency, all three modern options work. Baqsimi's needle-free delivery is its primary advantage for ease of use, but Gvoke and Zegalogue are clinically equivalent rescue options.
Which Alternative Should You Ask About?
Here's a quick guide:
Child ages 2-5: Ask about Gvoke (approved age 2+). Zegalogue is approved age 6+; Baqsimi is now approved age 1+.
Needle phobia in caregivers: Baqsimi is the only non-injection option. If Baqsimi truly isn't available, consider intense caregiver training on Gvoke's autoinjector.
Budget-conscious: Traditional glucagon kits (GlucaGen) may be less expensive. Always compare with GoodRx coupons and manufacturer savings programs for all options.
Insurance preference: Ask your pharmacist which glucagon product is at the lowest tier (Tier 1 or Tier 2) on your specific insurance formulary.
Keep Trying to Get Baqsimi
While you use an alternative, don't give up on getting Baqsimi if it's your preferred option. Use medfinder to search pharmacies in your area for Baqsimi availability. medfinder contacts pharmacies near you and texts you the results — so you can switch back to Baqsimi as soon as it's available.
Also, explore the savings programs covered in our guide to how to save money on Baqsimi in 2026 — you may find that the cost barrier is lower than you expect.
Frequently Asked Questions
The best alternative depends on your situation. Gvoke (glucagon autoinjector by Xeris) is the most similar in terms of ease of use — it's a ready-to-use injection that doesn't require mixing. Zegalogue (dasiglucagon) is another ready-to-use injectable option. All three have treatment success rates above 98% in clinical trials. Talk with your doctor about which is right for you.
Yes. Clinical trials show Gvoke and Baqsimi both achieve treatment success in over 98% of patients. Baqsimi tends to produce a lower peak blood glucose rise (168 mg/dL vs. 220 mg/dL for Gvoke), which may reduce post-treatment hyperglycemia. The main difference is route of administration: Baqsimi is nasal, Gvoke is subcutaneous injection.
Yes, traditional glucagon kits (like GlucaGen by Novo Nordisk) are effective and widely stocked. The key drawback is they require reconstitution — mixing a powder with liquid before injecting — which can be difficult in an emergency for untrained caregivers. If using a kit, ensure all caregivers practice the mixing process in a non-emergency setting.
Baqsimi was approved for ages 1 and older in 2025. Gvoke is approved for ages 2 and older. Zegalogue is approved for ages 6 and older. If your child is under 2, speak with your pediatrician immediately — they can recommend an appropriate dosing option and will likely refer to a pediatric endocrinologist.
Coverage varies by insurance plan and formulary. Some plans prefer Gvoke or Zegalogue over Baqsimi based on contract pricing, meaning the alternative may actually be covered at a lower copay. Check your plan's formulary or call member services to compare your out-of-pocket costs for each option.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Baqsimi also looked for:
More about Baqsimi
30,026 have already found their meds with Medfinder.
Start your search today.





